KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Assets Average (2016 - 2026)

Supernus Pharmaceuticals has reported Assets Average over the past 14 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly Assets Average rose 5.96% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 5.96% year-over-year, with the annual reading at $1.4 billion for FY2025, 6.61% up from the prior year.
  • Assets Average was $1.4 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Over five years, Assets Average peaked at $1.7 billion in Q1 2023 and troughed at $1.3 billion in Q4 2023.
  • The 5-year median for Assets Average is $1.5 billion (2021), against an average of $1.5 billion.
  • Year-over-year, Assets Average rose 28.14% in 2021 and then decreased 26.12% in 2024.
  • A 5-year view of Assets Average shows it stood at $1.6 billion in 2021, then rose by 4.67% to $1.7 billion in 2022, then dropped by 24.53% to $1.3 billion in 2023, then rose by 5.77% to $1.4 billion in 2024, then rose by 5.96% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Assets Average are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).